Clinical trial
HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer
NCT00401427 · National Cancer Institute, Naples, Other · Completed
Key facts
| NCT number | NCT00401427 |
|---|---|
| Title | HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer |
| Official title | A Single-centre Phase 2 Study of Vinorelbine Plus 3-weekly Trastuzumab in Metastatic Breast Cancer Overexpressing Her-2 |
| Lead sponsor | National Cancer Institute, Naples, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | trastuzumab, vinorelbine |
| Enrollment | 50 |
| Start date | Nov 1, 2002 |
| Primary completion | Jun 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Nov 20, 2006 |
| Last update posted | Jul 13, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: